Total Payments
$994,054
2024 Payments
$194,555
Companies
14
Transactions
271
Payment Breakdown by Category
Consulting$870,470 (87.6%)
Research$92,803 (9.3%)
Other$23,348 (2.3%)
Travel$6,203 (0.6%)
Food & Beverage$1,231 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $870,470 | 200 | 87.6% |
| Unspecified | $92,803 | 25 | 9.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17,348 | 13 | 1.7% |
| Travel and Lodging | $6,203 | 16 | 0.6% |
| Honoraria | $6,000 | 2 | 0.6% |
| Food and Beverage | $1,231 | 15 | 0.1% |
Payments by Type
General
$901,252
246 transactions
Research
$92,803
25 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $234,123 | 58 | $0 (2023) |
| Prometheus Laboratories Inc. | $203,603 | 58 | $0 (2018) |
| Merck Sharp & Dohme LLC | $182,783 | 61 | $0 (2024) |
| Daiichi Sankyo Inc. | $119,531 | 10 | $0 (2024) |
| EISAI INC. | $115,276 | 28 | $0 (2022) |
| Regeneron Pharmaceuticals, Inc. | $91,928 | 24 | $0 (2024) |
| PFIZER INC. | $18,603 | 13 | $0 (2017) |
| Amgen Inc. | $17,413 | 10 | $0 (2021) |
| Exelixis Inc. | $3,637 | 3 | $0 (2017) |
| Iovance Biotherapeutics, Inc. | $3,500 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $194,555 | 31 | Daiichi Sankyo Inc. ($107,656) |
| 2023 | $74,032 | 13 | E.R. Squibb & Sons, L.L.C. ($31,793) |
| 2022 | $81,438 | 22 | E.R. Squibb & Sons, L.L.C. ($45,848) |
| 2021 | $108,055 | 31 | Merck Sharp & Dohme Corporation ($51,625) |
| 2020 | $139,771 | 42 | E.R. Squibb & Sons, L.L.C. ($56,700) |
| 2019 | $101,602 | 31 | E.R. Squibb & Sons, L.L.C. ($46,382) |
| 2018 | $127,301 | 33 | Prometheus Laboratories Inc. ($74,562) |
| 2017 | $167,300 | 68 | Prometheus Laboratories Inc. ($129,041) |
All Payment Transactions
271 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $2,884.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 12/18/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $901.25 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | ||||||
| 11/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $2,884.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 11/26/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $1,261.75 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | ||||||
| 10/30/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $2,343.25 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 10/30/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $901.25 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | ||||||
| 10/10/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $1,261.75 | Research |
| Study: A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Pembrolizumab in Patients With Resectable Stage III and IV Melanoma • Category: ONCOLOGY | ||||||
| 10/09/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $11,562.50 | General |
| Category: ONCOLOGY | ||||||
| 10/08/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $2,343.25 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 10/08/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $721.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | ||||||
| 09/05/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $3,424.75 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | ||||||
| 08/21/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $8,387.50 | General |
| Category: VACCINE | ||||||
| 08/20/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $3,244.50 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 08/20/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $721.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | ||||||
| 08/14/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $19,062.50 | General |
| Category: ONCOLOGY | ||||||
| 07/30/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $5,587.75 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | ||||||
| 07/30/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $3,244.50 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 07/24/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $11,718.75 | General |
| Category: ONCOLOGY | ||||||
| 07/10/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $18,746.00 | Research |
| Study: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA • Category: ONCOLOGY | ||||||
| 06/26/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $16,250.00 | General |
| Category: ONCOLOGY | ||||||
| 05/22/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $5,795.00 | General |
| Category: ONCOLOGY | ||||||
| 05/15/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $12,656.25 | General |
| Category: ONCOLOGY | ||||||
| 05/07/2024 | Iovance Biotherapeutics, Inc. | Amtagvi (Drug) | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| Category: Oncology | ||||||
| 04/17/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $15,625.00 | General |
| Category: ONCOLOGY | ||||||
| 03/13/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $11,093.75 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA | Regeneron Pharmaceuticals, Inc. | $53,174 | 9 |
| A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA | Regeneron Pharmaceuticals, Inc. | $20,368 | 9 |
| A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma | Regeneron Pharmaceuticals, Inc. | $7,210 | 2 |
| A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma | Regeneron Pharmaceuticals, Inc. | $7,030 | 2 |
| A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Pembrolizumab in Patients With Resectable Stage III and IV Melanoma | Regeneron Pharmaceuticals, Inc. | $4,146 | 2 |
| P1/3 talimogene laherparepvec + MK-3475 Combo melanoma | Amgen Inc. | $875.00 | 1 |
About Dr. Janice Dutcher, M.D
Dr. Janice Dutcher, M.D is a Specialist healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1730242124.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Janice Dutcher, M.D has received a total of $994,054 in payments from pharmaceutical and medical device companies, with $194,555 received in 2024. These payments were reported across 271 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($870,470).
Ad
Practice Information
- Specialty Specialist
- Location New York, NY
- Active Since 12/18/2006
- Last Updated 10/26/2010
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1730242124
Products in Payments
- Enhertu (Drug) $119,531
- Lenvima (Drug) $115,276
- LENVIMA (Drug) $100,000
- OPDIVO (Biological) $91,125
- LIBTAYO (Biological) $71,559
- KEYTRUDA (Biological) $61,738
- IMLYGIC (Biological) $17,413
- MYLOTARG (Drug) $9,218
- Cabometyx (Drug) $3,637
- Amtagvi (Drug) $3,500
- PROLEUKIN (Drug) $480.00
- Proleukin (Drug) $418.84
- MYLOTARG (Biological) $19.44
- Nexavar (Drug) $11.40
- ELIQUIS (Drug) $2.62
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in New York
Dr. Eric Rose, M.d, M.D
Specialist — Payments: $4.9M
Specialist $4.9M
Dr. Baron Lonner, M.d, M.D
Specialist — Payments: $2.9M
Specialist $2.9M
Dr. Richard Spaide, Md, MD
Specialist — Payments: $1.7M
Specialist $1.7M
Dr. Marla Dubinsky, M.d, M.D
Specialist — Payments: $1.6M
Specialist $1.6M
Mrs. Naomi Nakao, M.d, M.D
Specialist — Payments: $1.1M
Specialist $1.1M
Grace Hyun, Md, MD
Specialist — Payments: $851,352
Specialist $851,352